BI 3706674 — Investigational Agent
KRAS Inhibitor · Phase 1 · Boehringer Ingelheim
Mechanism of Action
Oral small-molecule inhibitor of the SOS1-KRAS interaction (SOS1 GTP-loading blocker), suppressing nucleotide exchange to reactivate/reload KRAS, with activity aimed at KRAS-amplified and KRAS-mutant gastroesophageal tumors.
Investigational Indications
- KRAS-mutant/amplified gastric adenocarcinoma
- KRAS-mutant/amplified esophageal and gastroesophageal cancers